Marleen van Geest

AstraZeneca (Sweden)

Papers

1

Total Citations

7

H-Index

1

About

Marleen van Geest is a researcher specializing in analytical biochemistry and respiratory medicine, with a particular focus on the quantitative analysis of mucins—key glycoproteins implicated in airway diseases such as cystic fibrosis and chronic obstructive pulmonary disease. Her major contribution lies in developing a precise liquid chromatography–tandem mass spectrometry (LC-MS/MS) method that uses stable isotope-labeled peptides (¹³C,¹⁵N) as internal standards for accurate mucin quantification from sputum samples. This work, published in 2012 and cited 7 times, addresses a critical need for reliable biomarkers in respiratory research, enabling more consistent monitoring of disease progression and therapeutic responses. While her citation count is modest, the methodological rigor of her approach has provided a foundational tool for subsequent studies in mucin biology. Van Geest’s efforts exemplify how targeted analytical innovation can bridge the gap between complex glycoprotein chemistry and clinical application, offering a reproducible platform for investigating mucus pathophysiology. Her research underscores the importance of precise quantification in understanding and treating chronic respiratory conditions.

Research Focus

Key Achievements

1
H-Index
1
Papers
7
Total Citations
7
Avg Citations/Paper
🏆 Most Cited Paper
Liquid chromatography–tandem mass spectrometry approach for quantification of mucins from sputum using 13C,15N-labeled peptides as internal standards
7 citations · 2012
📈 Most Prolific Year: 2012 (1 Papers)
🤝 Key Collaborators: 3
🏛 Institutions: AstraZeneca (Sweden)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago